In this Webinar of May Awareness Month, Vissia Viglietta will be speaking on behalf of Wave Life Sciences. She would explain the results and all the good work they have been doing in improving from the updated on PRECISION-HD1 and PRECISION-HD2 medical trials. Wave would also present the promising approach that they are pursuing, the WVE-003 Project.
The WVE-003 Project
Wave is developing a third allele-selective HD candidate, WVE-003, which is designed to selectively target an undisclosed SNP on the mHTT mRNA transcript (SNP3), while leaving wtHTT protein relatively intact. In other words, Wave has the potential to provide allele-selective options for up to 80% of people with HD.
Speaker: Vissia Viglietta
Vice President Global Clinical Development and Medical Affairs at Wave Life Sciences
WHEN: 12. May, 19:00-20:30 Central European Time
Link here to register: https://bit.ly/3xp2ay2